Clinical Cancer Research

Table of Contents

AACR American Association for Cancer Research

December 1, 2018 • Volume 24 • Number 23

SPECIAL FEATURES

CCR Translations

Reviews

CLINICAL TRIAL BRIEF REPORT

CLINICAL TRIALS: TARGETED THERAPY

CLINICAL TRIALS: IMMUNOTHERAPY

Table of Contents

PRECISION MEDICINE AND IMAGING

Table of Contents

TRANSLATIONAL CANCER MECHANISMS AND THERAPY

Table of Contents

CORRECTIONS

EDITOR'S NOTES

AC icon indicates AuthorChoice
For more information please visit www.aacrjournals.org

Table of Contents

ABOUT THE COVER

The cover shows a section of a lung tumor from a patient with MET exon 14 mutant non-small cell lung cancer who developed acquired resistance to the MET inhibitor crizotinib. The crizotinib-resistant tumor was found to have acquired high-level amplification of wild-type KRAS and wild-type EGFR in nonoverlapping cells, as demonstrated by dual fluorescence *in situ* hybridization with a KRAS probe in red and an EGFR probe in green. For details, see the article by Bahcall and colleagues on page 5963 of this issue.



Clinical Cancer Research

24 (23)

Clin Cancer Res 2018;24:5785-6103.